Hyon K Choi

List of Publications by Year
in descending order

228	31,422	11235	5244
papers	citations	h-index	g-index

230	230	230	31145
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Care and Research, 2023, 75, 743-748.	1.5	13
2	Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working Group. Arthritis Care and Research, 2023, 75, 825-834.	1.5	22
3	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	1.5	23
4	Kidney Transplantation and Cardiovascular Events Among Patients With <scp>Endâ€Stage</scp> Renal Disease Due to Lupus Nephritis: A Nationwide Cohort Study. Arthritis Care and Research, 2022, 74, 1829-1834.	1.5	5
5	Lifetime Allergy Symptoms in <scp>IgG4â€Related</scp> Disease: A Caseâ€“Control Study. Arthritis Care and Research, 2022, 74, 1188-1195.	1.5	13
6	Does biologic therapy impact the development of PsA among patients with psoriasis?. Annals of the Rheumatic Diseases, 2022, 81, 80-86.	0.5	29
7	Derivation and Validation of Algorithms to Identify Patients With Immunoglobulinâ€•G4â€Related Disease Using Administrative Claims Data. ACR Open Rheumatology, 2022, , .	0.9	3
8	Adherence to 2020 to 2025 Dietary Guidelines for Americans and the Risk of New-Onset Female Gout. JAMA Internal Medicine, 2022, 182, 254.	2.6	21
9	Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease. Annals of Internal Medicine, 2022, 175, 461-470.	2.0	17
10	Protonâ€Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Populationâ€Based Study. Arthritis Care and Research, 2022, 74, 2059-2065.	1.5	6
11	Racial Disparities in the Modern Gout Epidemic. Journal of Rheumatology, 2022, 49, 443-446.	1.0	3
12	The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial. Rheumatology and Therapy, 2022, 9, 497-508.	1.1	1
13	Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nature Reviews Rheumatology, 2022, 18, 97-111.	3.5	45
14	Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years. Annals of the Rheumatic Diseases, 2022, 81, 556-563.	0.5	14
15	Alcohol consumption and the risk of mortality and myocardial infarction in patients with rheumatoid arthritis.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
16	The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. Annals of the Rheumatic Diseases, 2022, 81, 1438-1445.	0.5	7
17	Exploration of machine learning methods to predict systemic lupus erythematosus hospitalizations. Lupus, 2022, 31, 1296-1305.	0.8	9
18	Hypouricemia and Mortality Risk in the US General Population. Arthritis Care and Research, 2021, 73, 1171-1179.	1.5	14

#	Article	IF	Citations
19	Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population. Arthritis Care and Research, 2021, 73, 1219-1223.	1.5	23
20	Epidemiology of Depression and Anxiety in Gout: A Systematic Review and Metaanalysis. Journal of Rheumatology, 2021, 48, 129-137.	1.0	14
21	Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. Journal of Human Genetics, 2021, 66, 161-169.	1.1	6
22	Effects of Dietary Patterns on Serum Urate: Results From a Randomized Trial of the Effects of Diet on Hypertension. Arthritis and Rheumatology, 2021, 73, 1014-1020.	2.9	33
23	COVIDâ€19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis and Rheumatology, 2021, 73, 914-920.	2.9	117
24	Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Annals of the Rheumatic Diseases, 2021, 80, 660-666.	0.5	74
25	Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine. JAMA Internal Medicine, 2021, 181, 284.	2.6	7
26	Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. Lancet Rheumatology, The, 2021, 3, e131-e137.	2.2	61
27	A Randomized Pilot Study of DASH Patterned Groceries on Serum Urate in Individuals with Gout. Nutrients, 2021, 13, 538.	1.7	18
28	ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry. Journal of Rheumatology, 2021, 48, 1060-1064.	1.0	5
29	Topic modeling to characterize the natural history of ANCA-Associated vasculitis from clinical notes: A proof of concept study. Seminars in Arthritis and Rheumatism, 2021, 51, 150-157.	1.6	5
30	Effects of dietary macronutrients on serum urate: results from the OmniHeart trial. American Journal of Clinical Nutrition, 2021, 113, 1593-1599.	2.2	10
31	Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. Arthritis and Rheumatology, 2021, 73, 721-724.	2.9	10
32	The association of smoking with immunoglobulin G4â€“related disease: a caseâ€“control study. Rheumatology, 2021, 60, 5310-5317.	0.9	18
33	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout. RMD Open, 2021, 7, e001623.	1.8	6
34	Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel. ACR Open Rheumatology, 2021, 3, 341-348.	0.9	3
35	Dietary and Lifestyle-Centered Approach in Gout Care and Prevention. Current Rheumatology Reports, 2021, 23, 51.	2.1	21
36	Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nature Reviews Rheumatology, 2021, 17, 633-641.	3.5	36

#	Article	IF	Citations
37	Identification and characterization of peripheral vascular color-coded DECT lesions in gout and non-gout patients: The VASCURATE study. Seminars in Arthritis and Rheumatism, 2021, 51, 895-902.	1.6	15
38	Genetic and Physiological Effects of Insulin on Human Urate Homeostasis. Frontiers in Physiology, 2021, 12, 713710.	1.3	17
39	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatology, The, 2021, 3, e638-e647.	2.2	30
40	Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. Arthritis and Rheumatology, 2021, 73, 2096-2104.	2.9	49
41	Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. ACR Open Rheumatology, 2021, 3, 834-841.	0.9	9
42	Medications for gout and its comorbidities: mutual benefits?. Current Opinion in Rheumatology, 2021, 33, 145-154.	2.0	2
43	The role of diet in hyperuricemia and gout. Current Opinion in Rheumatology, 2021, 33, 135-144.	2.0	60
44	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and highâ€sensitivity Câ€reactive protein in <scp>CANTOS</scp>. Arthritis Care and Research, 2021, , .	1.5	3
45	Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis. Annals of the Rheumatic Diseases, 2020, 79, e40-e40.	0.5	4
46	Treatment Delays Associated With Prior Authorization for Infusible Medications: A Cohort Study. Arthritis Care and Research, 2020, 72, 1543-1549.	1.5	20
47	Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout â€“ A cluster pattern analysis of dual-energy CT. Seminars in Arthritis and Rheumatism, 2020, 50, 54-58.	1.6	7
48	Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia. Arthritis and Rheumatology, 2020, 72, 157-165.	2.9	68
49	Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid. Arthritis and Rheumatology, 2020, 72, 234-241.	2.9	9
50	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Annals of the Rheumatic Diseases, 2020, 79, 77-87.	0.5	390
51	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4â€Related Disease. Arthritis and Rheumatology, 2020, 72, 7-19.	2.9	292
52	Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT). Diabetes Care, 2020, 43, 2812-2820.	4.3	49
53	Mortality trends in polymyositis and dermatomyositis: A general population-based study. Seminars in Arthritis and Rheumatism, 2020, 50, 834-839.	1.6	7
54	Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US â€˜hot spotâ€™. Annals of the Rheumatic Diseases, 2020, 79, 1156-1162.	0.5	217

#	Article	IF	Citations
55	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.0	41
56	Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race. Annals of Allergy, Asthma and Immunology, 2020, 125, 190-195.e2.	0.5	21
57	Identification of Cardiovascular Monosodium Urate Crystal Deposition in Patients With Gout Using Dual-Energy Computed Tomography. JAMA Cardiology, 2020, 5, 486.	3.0	8
58	Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. Human Molecular Genetics, 2020, 29, 923-943.	1.4	40
59	Association of Tramadol Use With Risk of Hip Fracture. Journal of Bone and Mineral Research, 2020, 35, 631-640.	3.1	20
60	Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study. Seminars in Arthritis and Rheumatism, 2020, 50, 1382-1386.	1.6	8
61	Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis. ACR Open Rheumatology, 2020, 2, 261-268.	0.9	10
62	Estimation of Primary Prevention of Gout in Men Through Modification of Obesity and Other Key Lifestyle Factors. JAMA Network Open, 2020, 3, e2027421.	2.8	37
63	Response to: â€˜Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritisâ€™. Annals of the Rheumatic Diseases, 2019, 78, e79-e79.	0.5	1
64	Risk of gout flares after vaccination: a prospective case cross-over study. Annals of the Rheumatic Diseases, 2019, 78, 1601-1604.	0.5	20
65	Tramadol and Mortality in Patients With Osteoarthritisâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 322, 466.	3.8	2
66	Reply. Arthritis and Rheumatology, 2019, 71, 1967-1968.	2.9	0
67	171.â€ƒCARDIOVASCULAR DISEASE IS THE MOST COMMON CAUSE OF DEATH IN ANCA-ASSOCIATED VASCULITIS (AAV). Rheumatology, 2019, 58, .	0.9	2
68	172.â€ƒTHE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV). Rheumatology, 2019, 58, .	0.9	0
69	Renal Transplantation and Survival Among Patients With Lupus Nephritis. Annals of Internal Medicine, 2019, 170, 240.	2.0	48
70	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1879-1887.	2.9	23
71	Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Rheumatology, 2019, 58, 2122-2129.	0.9	29
72	Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout. Hypertension, 2019, 74, 95-101.	1.3	31

#	Article	IF	Citations
73	Recorded Penicillin Allergy and Risk of Mortality: a Population-Based Matched Cohort Study. Journal of General Internal Medicine, 2019, 34, 1685-1687.	1.3	46
74	Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis. JAMA - Journal of the American Medical Association, 2019, 321, 969.	3.8	155
75	OP0115â€…GENERAL AND SEX-SPECIFIC PREDICTORS OF PSA AMONG PATIENTS WITH PSORIASIS. , 2019, , .		0
76	FRI0458â€…OBJECTIVE MEASURES OF PSORIASIS SEVERITY AND THE RISK FOR PSA: RESULTS FROM THE INCIDENT HEALTH OUTCOMES AND PSORIASIS EVENTS PROSPECTIVE COHORT STUDY. , 2019, , .		1
77	Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general populationâ€“based cohort study. Cmaj, 2019, 191, E1070-E1077.	0.9	12
78	Response to: â€˜Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flaresâ€™ by Didierlaurent et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216670.	0.5	0
79	Gout. Nature Reviews Disease Primers, 2019, 5, 69.	18.1	326
80	The Risk of Gout Among Patients With Sleep Apnea: A Matched Cohort Study. Arthritis and Rheumatology, 2019, 71, 154-160.	2.9	19
81	Allâ€Cause and Causeâ€Specific Mortality Trends of Endâ€Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. Arthritis and Rheumatology, 2019, 71, 403-410.	2.9	38
82	Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Annals of the Rheumatic Diseases, 2019, 78, 406-412.	0.5	248
83	No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Medicine, 2019, 16, e1002725.	3.9	97
84	Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007â€“2016. Arthritis and Rheumatology, 2019, 71, 991-999.	2.9	527
85	Reply. Arthritis and Rheumatology, 2019, 71, 481-482.	2.9	0
86	Allâ€Cause and Causeâ€Specific Mortality in Patients With Granulomatosis With Polyangiitis: A Populationâ€Based Study. Arthritis Care and Research, 2019, 71, 155-163.	1.5	26
87	Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213089.	0.5	38
88	Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212905.	0.5	29
89	Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal Deposition. Arthritis and Rheumatology, 2018, 70, 1182-1191.	2.9	45
90	Improving Mortality in Endâ€Stage Renal Disease Due to Granulomatosis With Polyangiitis (Wegener's) From 1995 to 2014: Data From the United States Renal Data System. Arthritis Care and Research, 2018, 70, 1495-1500.	1.5	10

#	Article	IF	Citations
91	Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999â€“2014). Rheumatology, 2018, 57, 337-344.	0.9	92
92	Response to: â€˜Smoking paradox in the development of psoriatic arthritis among patients with psoriasisâ€™ by Lee and Song. Annals of the Rheumatic Diseases, 2018, 77, e76-e76.	0.5	2
93	Mitochondrial genetic variation and gout in MÄori and Pacific people living in Aotearoa New Zealand. Annals of the Rheumatic Diseases, 2018, 77, 571-578.	0.5	30
94	Sharp decline in hydroxychloroquine dosingâ€”analysis of 17,797 initiators from 2007 to 2016. Clinical Rheumatology, 2018, 37, 1853-1859.	1.0	12
95	Statin use and mortality in gout: A general population-based cohort study. Seminars in Arthritis and Rheumatism, 2018, 48, 449-455.	1.6	11
96	Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. European Heart Journal, 2018, 39, 3608-3614.	1.0	115
97	Response to: â€˜Is optimizing gout treatment the key to closing the mortality gap in gout patients?â€™ by Brinck et al. Annals of the Rheumatic Diseases, 2018, 77, e3-e3.	0.5	0
98	Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: A marginal structural model analysis in the Nursesâ€™ Health Study. Seminars in Arthritis and Rheumatism, 2018, 47, 639-648.	1.6	42
99	Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. Annals of the Rheumatic Diseases, 2018, 77, 119-123.	0.5	67
100	Hydroxychloroquine retinopathy â€” implications of research advances for rheumatology care. Nature Reviews Rheumatology, 2018, 14, 693-703.	3.5	148
101	Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Network Open, 2018, 1, e184169.	2.8	210
102	The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases. Journal of Rheumatology, 2018, 45, 1689-1695.	1.0	19
103	Risk of meticillin resistant Staphylococcus aureus and Clostridium difficile in patients with a documented penicillin allergy: population based matched cohort study. BMJ: British Medical Journal, 2018, 361, k2400.	2.4	223
104	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Research and Therapy, 2018, 20, 133.	1.6	30
105	Gout and the Risk of Incident Erectile Dysfunction: A Body Mass Index-matched Population-based Study. Journal of Rheumatology, 2018, 45, 1192-1197.	1.0	15
106	New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis and Rheumatology, 2018, 70, 1702-1709.	2.9	86
107	Obesity Paradox in Recurrent Attacks of Gout in Observational Studies: Clarification and Remedy. Arthritis Care and Research, 2017, 69, 561-566.	1.5	26
108	Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. Journal of Rheumatology, 2017, 44, 388-396.	1.0	111

#	Article	IF	Citations
109	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Annals of the Rheumatic Diseases, 2017, 76, 543-546.	0.5	154
110	Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Annals of the Rheumatic Diseases, 2017, 76, 521-525.	0.5	77
111	Improved survival in rheumatoid arthritis: a general population-based cohort study. Annals of the Rheumatic Diseases, 2017, 76, 408-413.	0.5	85
112	The unclosing premature mortality gap in gout: a general population-based study. Annals of the Rheumatic Diseases, 2017, 76, 1289-1294.	0.5	81
113	The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. Annals of the Rheumatic Diseases, 2017, 76, 882-885.	0.5	62
114	Does knee replacement surgery for osteoarthritis improve survival? The jury is still out. Annals of the Rheumatic Diseases, 2017, 76, 140-146.	0.5	15
115	Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics, 2017, 35, 1073-1085.	1.7	9
116	Populationâ€Specific Resequencing Associates the ATPâ€Binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand MÄori and Pacific Men. Arthritis and Rheumatology, 2017, 69, 1461-1469.	2.9	46
117	Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. Rheumatology, 2017, 56, 907-911.	0.9	59
118	The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary SjÃ¶gren Syndrome: A General Population-based Study. Journal of Rheumatology, 2017, 44, 1184-1189.	1.0	39
119	Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. Arthritis and Rheumatology, 2017, 69, 479-482.	2.9	15
120	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 176-184.	2.9	22
121	Effects of Febuxostat in Early Gout. Arthritis and Rheumatology, 2017, 69, 2386-2395.	2.9	71
122	Meloxicam and risk of myocardial infarction: a population-based nested caseâ€“control study. Rheumatology International, 2017, 37, 2071-2078.	1.5	12
123	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nature Reviews Rheumatology, 2017, 13, 561-568.	3.5	74
124	Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Annals of the Rheumatic Diseases, 2017, 76, 1737-1742.	0.5	28
125	The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Seminars in Arthritis and Rheumatism, 2017, 46, 594-600.	1.6	67
126	Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011. Arthritis Care and Research, 2017, 69, 758-762.	1.5	34

#	Article	IF	Citations
127	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis Care and Research, 2017, 69, 1004-1010.	1.5	11
128	Nationwide Trends in Hospitalizations and Inâ€Hospital Mortality in Granulomatosis With Polyangiitis (Wegener's). Arthritis Care and Research, 2017, 69, 915-921.	1.5	32
129	The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Seminars in Arthritis and Rheumatism, 2017, 46, 451-456.	1.6	83
130	The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study. BMJ: British Medical Journal, 2017, 357, j1794.	2.4	144
131	Dose-response relationship between lower serum magnesium level and higher prevalence of knee chondrocalcinosis. Arthritis Research and Therapy, 2017, 19, 236.	1.6	32
132	A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS ONE, 2017, 12, e0173997.	1.1	52
133	Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology, 2016, 55, kev336.	0.9	32
134	The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study. Annals of the Rheumatic Diseases, 2016, 75, 148-154.	0.5	60
135	Association of IgG4â€Related Disease With History of Malignancy. Arthritis and Rheumatology, 2016, 68, 2283-2289.	2.9	90
136	Validity of ankylosing spondylitis diagnoses in The Health Improvement Network. Pharmacoepidemiology and Drug Safety, 2016, 25, 399-404.	0.9	35
137	Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Populationâ€Based Study. Arthritis Care and Research, 2016, 68, 246-253.	1.5	40
138	Racial disparities in the risk of Stevensâ€"Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Seminars in Arthritis and Rheumatism, 2016, 46, 253-258.	1.6	43
139	Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. Gastroenterology, 2016, 151, 351-363.e28.	0.6	74
140	Insight into rheumatological cause and effect through the use of Mendelian randomization. Nature Reviews Rheumatology, 2016, 12, 486-496.	3.5	46
141	Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid. Arthritis and Rheumatology, 2016, 68, 3002-3009.	2.9	90
142	Myeloperoxidaseâ€"Antineutrophil Cytoplasmic Antibody (ANCA)â€"Positive and ANCAâ€Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis and Rheumatology, 2016, 68, 2945-2952.	2.9	75
143	Opposing effects of sodium intake on uric acid and blood pressure and their causal implication. Journal of the American Society of Hypertension, 2016, 10, 939-946.e2.	2.3	9
144	Trends in Gout and Rheumatoid Arthritis Hospitalizations in the United States, 1993-2011. JAMA - Journal of the American Medical Association, 2016, 315, 2345.	3.8	87

#	Article	IF	Citations
145	Editorial: Pursuit of a Dualâ€Benefit Antigout Drug: A First Look at Arhalofenate. Arthritis and Rheumatology, 2016, 68, 1793-1796.	2.9	7
146	Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Populationâ€Based Study. Arthritis and Rheumatology, 2016, 68, 2752-2759.	2.9	54
147	Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study. Annals of the Rheumatic Diseases, 2016, 75, 91-95.	0.5	69
148	Early Cardiovascular Disease After the Diagnosis of Systemic Sclerosis. American Journal of Medicine, 2016, 129, 324-331.	0.6	35
149	Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. Annals of the Rheumatic Diseases, 2016, 75, 110-116.	0.5	66
150	Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Rheumatology, 2016, 55, 1099-1105.	0.9	24
151	Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology, 2016, 55, 1000-1008.	0.9	151
152	Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nature Genetics, 2016, 48, 189-194.	9.4	211
153	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases, 2016, 75, 1166-1169.	0.5	196
154	Increased risk of cardiovascular disease in giant cell arteritis: a general populationâ€“based study. Rheumatology, 2016, 55, 33-40.	0.9	64
155	Improved survival in granulomatosis with polyangiitis: A general population-based study. Seminars in Arthritis and Rheumatism, 2016, 45, 483-489.	1.6	55
156	Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. Annals of the Rheumatic Diseases, 2016, 75, 1315-1320.	0.5	53
157	Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Annals of the Rheumatic Diseases, 2016, 75, 547-551.	0.5	119
158	The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. PLoS ONE, 2016, 11, e0147939.	1.1	31
159	Total Joint Arthroplasty and the Risk of Myocardial Infarction: A General Population, Propensity Scoreâ€“Matched Cohort Study. Arthritis and Rheumatology, 2015, 67, 2771-2779.	2.9	43
160	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2557-2568.	2.9	393
161	Sleep Apnea and the Risk of Incident Gout: A Populationâ€Based, Body Mass Indexâ€“Matched Cohort Study. Arthritis and Rheumatology, 2015, 67, 3298-3302.	2.9	30
162	Septic arthritis in gout patients: a population-based cohort study. Rheumatology, 2015, 54, 2095-2099.	0.9	24

#	Article	IF	Citations
163	Allopurinol initiation and all-cause mortality in the general population. Annals of the Rheumatic Diseases, 2015, 74, 1368-1372.	0.5	58
164	The economic burden of gout: A systematic review. Seminars in Arthritis and Rheumatism, 2015, 45, 75-80.	1.6	84
165	Surgical site infection in hand surgery. International Orthopaedics, 2015, 39, 2191-2198.	0.9	37
166	An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Seminars in Arthritis and Rheumatism, 2015, 45, 174-183.	1.6	82
167	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1789-1798.	0.5	545
168	The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study. Seminars in Arthritis and Rheumatism, 2015, 45, 195-201.	1.6	61
169	Lack of geneâ€“diuretic interactions on the risk of incident gout: the Nursesâ€™ Health Study and Health Professionals Follow-up Study. Annals of the Rheumatic Diseases, 2015, 74, 1394-1398.	0.5	18
170	Nocturnal Risk of Gout Attacks. Arthritis and Rheumatology, 2015, 67, 555-562.	2.9	47
171	Psoriasis, psoriatic arthritis and risk of gout in US men and women. Annals of the Rheumatic Diseases, 2015, 74, 1495-1500.	0.5	67
172	Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 326-332.	0.5	373
173	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	1.1	34
174	Crystal deposition diseases. Current Opinion in Rheumatology, 2014, 26, 151.	2.0	0
175	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	13.7	1,974
176	The Comparative Safety of Tumor Necrosis FactorÂInhibitors in Rheumatoid Arthritis: AÂMeta-analysis Update of 44 Trials. American Journal of Medicine, 2014, 127, 1208-1232.	0.6	100
177	Bariatric surgery as urate-lowering therapy in severe obesity. Annals of the Rheumatic Diseases, 2014, 73, 791-793.	0.5	14
178	Epidemiology of Gout. Rheumatic Disease Clinics of North America, 2014, 40, 155-175.	0.8	282
179	The Genetic Basis of Gout. Rheumatic Disease Clinics of North America, 2014, 40, 279-290.	0.8	35
180	Selection bias in rheumatic disease research. Nature Reviews Rheumatology, 2014, 10, 403-412.	3.5	93

#	Article	IF	Citations
181	The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Annals of the Rheumatic Diseases, 2013, 72, 1182-1187.	0.5	112
182	Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nature Genetics, 2013, 45, 145-154.	9.4	675
183	Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ: British Medical Journal, 2012, 344, d8190-d8190.	2.4	197
184	Risk factors for pseudogout in the general population. Rheumatology, 2012, 51, 2070-2074.	0.9	48
185	Dual energy CT in gout: a prospective validation study. Annals of the Rheumatic Diseases, 2012, 71, 1466-1471.	0.5	178
186	Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008. American Journal of Medicine, 2012, 125, 679-687.e1.	0.6	490
187	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	1.5	1,268
188	Hyperuricemia and incident hypertension: A systematic review and metaâ€analysis. Arthritis Care and Research, 2011, 63, 102-110.	1.5	571
189	Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis and Rheumatism, 2011, 63, 3136-3141.	6.7	1,385
190	Genetics of gout. Current Opinion in Rheumatology, 2010, 22, 144-151.	2.0	57
191	Fructose-Rich Beverages and Risk of Gout in Women. JAMA - Journal of the American Medical Association, 2010, 304, 2270.	3.8	247
192	Coffee consumption and risk of incident gout in women: the Nursesâ€™ Health Study. American Journal of Clinical Nutrition, 2010, 92, 922-927.	2.2	90
193	Impact of diabetes against the future risk of developing gout. Annals of the Rheumatic Diseases, 2010, 69, 2090-2094.	0.5	83
194	Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Annals of the Rheumatic Diseases, 2010, 69, 1162-1164.	0.5	124
195	Vitamin C Intake and the Risk of Gout in Men. Archives of Internal Medicine, 2009, 169, 502.	4.3	155
196	Hyperuricemia and risk of stroke: A systematic review and metaâ€analysis. Arthritis and Rheumatism, 2009, 61, 885-892.	6.7	388
197	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis and Rheumatism, 2008, 58, 26-35.	6.7	4,029
198	Sugarâ€sweetened soft drinks, diet soft drinks, and serum uric acid level: The third national health and nutrition examination survey. Arthritis and Rheumatism, 2008, 59, 109-116.	6.7	337

#	Article	IF	Citations
199	Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ: British Medical Journal, 2008, 336, 309-312.	2.4	443
200	Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease. Circulation, 2007, 116, 894-900.	1.6	546
201	Intake of Added Sugar and Sugar-Sweetened Drink and Serum Uric Acid Concentration in US Men and Women. Hypertension, 2007, 50, 306-312.	1.3	163
202	Prevalence of the Metabolic Syndrome in Individuals with Hyperuricemia. American Journal of Medicine, 2007, 120, 442-447.	0.6	505
203	Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis and Rheumatism, 2007, 57, 109-115.	6.7	386
204	Coffee consumption and risk of incident gout in men: A prospective study. Arthritis and Rheumatism, 2007, 56, 2049-2055.	6.7	160
205	Coffee, tea, and caffeine consumption and serum uric acid level: The third national health and nutrition examination survey. Arthritis and Rheumatism, 2007, 57, 816-821.	6.7	185
206	Epidemiology of Crystal Arthropathy. Rheumatic Disease Clinics of North America, 2006, 32, 255-273.	0.8	30
207	Dietary risk factors for rheumatic diseases. Current Opinion in Rheumatology, 2005, 17, 141-146.	2.0	62
208	Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The Third National Health and Nutrition Examination Survey. Arthritis and Rheumatism, 2005, 52, 283-289.	6.7	478
209	Glucocorticoid use and serum lipid levels in US adults: The third national health and nutrition examination survey. Arthritis and Rheumatism, 2005, 53, 528-535.	6.7	66
210	Diet, alcohol, and gout: How do we advise patients given recent developments?. Current Rheumatology Reports, 2005, 7, 220-226.	2.1	25
211	Obesity, Weight Change, Hypertension, Diuretic Use, and Risk of Gout in Men. Archives of Internal Medicine, 2005, 165, 742.	4.3	505
212	Dairy Consumption and Risk of Type 2 Diabetes Mellitus in Men. Archives of Internal Medicine, 2005, 165, 997.	4.3	315
213	Pathogenesis of Gout. Annals of Internal Medicine, 2005, 143, 499.	2.0	784
214	Gout: epidemiology and lifestyle choices. Current Opinion in Rheumatology, 2005, 17, 341-5.	2.0	76
215	Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. Journal of Rheumatology, 2005, 32, 2311-6.	1.0	73
216	Beer, liquor, and wine consumption and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis and Rheumatism, 2004, 51, 1023-1029.	6.7	236

#	Article	IF	Citations
217	Observational research in rheumatic disorders. Rheumatic Disease Clinics of North America, 2004, 30, 685-699.	0.8	4
218	Prospective cohorts and rheumatic disease research. Rheumatic Disease Clinics of North America, 2004, 30, 799-817.	0.8	0
219	Purine-Rich Foods, Dairy and Protein Intake, and the Risk of Gout in Men. New England Journal of Medicine, 2004, 350, 1093-1103.	13.9	891
220	Alcohol intake and risk of incident gout in men: a prospective study. Lancet, The, 2004, 363, 1277-1281.	6.3	611
221	Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet, The, 2002, 359, 1173-1177.	6.3	974
222	A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 1156-65.	1.0	49
223	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis and Rheumatism, 2000, 43, 226-231.	6.7	165
224	Drug-associated antineutrophil cytoplasmic antibodyâ€“positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis and Rheumatism, 2000, 43, 405.	6.7	390
225	A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 2316-2327.	6.7	101
226	Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis and Rheumatism, 2000, 43, 2488-2492.	6.7	48
227	Alternating antineutrophil cytoplasmic antibody specificity: Drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthritis and Rheumatism, 1999, 42, 384-388.	6.7	43
228	Alcohol consumption and the risk of mortality and myocardial infarction in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 0, , .	0.4	0